U.S. flag An official website of the United States government.
Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

i

Effect of Age at Vaccination on Rotavirus Vaccine Effectiveness in Bolivian Infants

Supporting Files
File Language:
English


Details

  • Alternative Title:
    Pediatr Infect Dis J
  • Personal Author:
  • Description:
    Background

    Rotavirus vaccines are less effective in developing countries versus developed countries. One hypothesis for this difference in performance is that higher levels of maternal antibodies in developing countries may interfere with vaccine response, suggesting that delayed dosing could be beneficial. The present analysis aims to assess whether rotavirus vaccine effectiveness (VE) varies by age at vaccination during routine use in Bolivia.

    Methods

    Data were merged from two post-licensure evaluations of monovalent rotavirus vaccine (RV1) in Bolivia, where two doses of RV1 are recommended at two and four months of age. For each dose, children were classified as receiving each dose “early,” “on-time,” or “late.” Stratified unconditional logistic regression models were used to estimate VE, using unvaccinated children as the referent. VE was calculated as (1 – odds ratio) × 100%. Models were adjusted for hospital, age, and time since RV1 introduction (via including terms for month and year of birth).

    Results

    VE for two doses of RV1 tended to be higher in infants receiving the first dose early (VE 92%; 95% confidence interval [CI] [70%, 98%]), when compared to infants receiving their first dose on time (72% [62%, 81%]) or late (68% [51%, 79%]). Estimates of VE were not substantially different when comparing children by age at second dose (early: VE 76% [50%, 89%]; on time: VE 70% [50%, 89%]; late: VE 75% [60%, 84%]), including all children.

    Conclusions

    Our results indicate that early administration may improve VE and support the current WHO recommendations for the RV1 schedule.

  • Subjects:
  • Source:
    Pediatr Infect Dis J. 37(8):e216-e221
  • Pubmed ID:
    29341984
  • Pubmed Central ID:
    PMC6043377
  • Document Type:
  • Funding:
  • Place as Subject:
  • Volume:
    37
  • Issue:
    8
  • Collection(s):
  • Main Document Checksum:
    urn:sha256:d2b83e19c96cf1b2ddd7cec5b17c4c2dc421881483fea607046ec35245f5eb9c
  • Download URL:
  • File Type:
    Filetype[PDF - 202.82 KB ]
File Language:
English
ON THIS PAGE

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.